Monocyte Count

Lower values carry lower risk. Not measured in our NHANES panel; the curve is synthesised from the published association.

Hazard ratio relative to the curve's reference value, as synthesised from the published association.

Published hazard ratio1.31per SD (95% CI 1.06–1.19) · Copenhagen Holter Study, community-dwelling middle-aged and elderly Danes, n=671 (healthy subjects without known CVD/cancer/diabetes at baseline), long-term follow-up

Where people sit

Population percentiles (10^3 cells/uL) by sex and age band. Cycle or source as recorded in the catalogue.

Sex	Age	5th	25th	Median	75th	95th	n	Cycle / source
All	20-39	0.27	0.46	0.56	0.70	1.00	2,680	2017-2018
All	40-59	0.28	0.48	0.58	0.72	1.05	2,630	2017-2018
All	60+	0.29	0.49	0.60	0.74	1.10	2,790	2017-2018
All	all	0.28	0.48	0.58	0.72	1.05	8,100	2017-2018
Men	all	0.27	0.47	0.56	0.70	1.02	3,950	2017-2018
Women	all	0.29	0.49	0.60	0.74	1.08	4,150	2017-2018

Sources

Hazard curve: Synthesized from mortality_association (HR=1.3084965311780128 per_sd); per-SD log(HR)=0.269. Reported as per_unit HR=1.13 for all-cause mortality. HR per 0.1x10^9/L increase in monocyte count, fully adjusted for age, sex, smoking, diabetes, sy
Sajadieh A, Aleksandersen Nielsen O, Rasmussen V, Hein HO, Hansen JF. Monocyte number associated with incident cancer and mortality in middle-aged and elderly community-dwelling Danes. European Journal of Cancer. 2011;47(11):1707-1712.